Журнал кардиореспираторных исследований 2025. №2/2
Subject of the article
CHRONIC KIDNEY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS (72-76)
Authors
Akhmedova Gulchehra Abdullayevna, Khasanov Farrukh Sherali ugli, Eshmuratov Sardor Eldor ugli, Uralov Rustam Sherbek ugli, Khamraev Khamza Khamidullaevich
Institution
Samarkand State medical university
Abstract
According to recent studies, chronic kidney disease (CKD) is significantly more prevalent in patients with rheumatoid arthritis (RA) than in those without RA, and is closely associated with the risk of cardiovascular complications and high mortality. In addition to the influence of general population risk factors for CKD, the activity of RA itself is an independent predictor of decreased glomerular filtration rate <60 ml/min/1.73 m2 in RA patients. Possible morphological variants and mechanisms of kidney damage are also considered. The introduction of pharmacotherapy with disease-modifying antirheumatic drugs and innovative biologic and targeted therapies in recent years has changed the course and outcomes of RA, including the frequency and pattern of renal manifestations.
Key words
rheumatoid arthritis, chronic kidney disease, glomerular filtration rate, amyloidosis, disease-modifying therapy.
Literature
1. Насонов Е.Л. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-19 [Nasonov EL. Pharmacotherapy of rheumatoid arthritis: a new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.)]. https://doi.org/10.14412/1995-4484-2017-409-419 2. Tokoroyama T, Ando M, Setoguchi K, Tsuchiya K, Nitta K. Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. Nephrol Dial Transplant. 2016;0:1-8. doi: 10.1093/ndt/gfw315 3. Kim HW, Lee CK, Cha HS, Choe JY, Park EJ, Kim J. Effect of antitumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease. Rheumatol 10.1007/s00296-014-3146-4 Int. 2015;3 4. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., Мартынов А.И., Яхно Н.Н., Арутюнов Г.П., Алексеева Л.И., Абузарова Г.Р., Евсеев М.А., Кукушкин М.Л., Копенкин С.С., Лила А.М., Лапина Т.Л., Новикова Д.С., Попкова Т.В., Ребров А.П., Скоробогатых К.В., Чичасова Н.В. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29 [Karateev AE, Nasonov EL, Ivashkin VT, Martynov AI, Yakhno N.N., Arutyunov GP, Alekseeva LI, Abuzarova GR, Evseev MA, Kukushkin ML, Kopenkin SS, Lila AM, Lapina TL, Novikova DS, Popkova TV, Rebrov AP, Skorobogatykh KV, Chichasova NV. Rational use of nonsteroidal anti- inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29 (In Russ.)]. https://doi.org/10.14412/1995-4484-2018-1-29 5. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford). 2008;47:350- 4. 6. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206. 7. Huerta C, Castellsague J, Varas-Lorenzo C, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005 Mar;45(3):531-9. doi: 10.1053/j.ajkd.2004.12.005 8. Оранский С.П. Хроническая болезнь почек при ревматоидно артрите: ассоциация с сердечно-сосудистым риском. Фундаментальные исследования. 2013;12(2):285-8 [Oransky SP. Chronic kidney disease in rheumatoid arthritis: an association with cardiovascular risk. Basic research. 2013;12(2):285-8 (In Russ)]. 9. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y. Inflammation as a Risk of Developing Chronic Kidney Disease in Rheumatoid Arthritis. PLOS ONE. 2016. doi: 10.1371/journal.pone.016022 10. Ребров А.П., Тяпкина М.А., Волошинова Е. В. Субклиническое поражение почек у пациентов с ревматоидным артритом. Лечащий врач. 2012;4:40-2 [Rebrov AP, Tyapkina MA, Voloshinova EV. Subclinical kidney damage in patients with rheumatoid arthritis. Lechaschi Vrach. 2012;4:40-2 (In Russ.)]. 11. Toblli JE, Bevione P, Di Gennaro F, Madalena L, Cao G, Angerosa M. Understanding the mechanisms of proteinuria: therapeutic implications. Int J Nephrol. 2012:546039. doi: 10.1155/2012/546039 12. Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, et al. C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol. 2001;55(5):365-70. 13. Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ. C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(12):1780-4. 14. Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol. 2002;12:148-54. 15. Мухин Н.А. Амилоидоз почек: вопросы клиники и патогенеза: Автореф. дис. … докт. мед. наук. М., 1981 [Mukhin NA. Kidney amyloidosis: issues of the clinic and pathogenesis: Avtoref. diss… MD, Moscow, 1981 (In Russ.)]. 16. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore). 1991;70:246. 17. Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Kautiainen H, Hakala M. Steep decline in the incidence of renal replacement therapy for amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol. 2009;38:403. 18. Góis M, Carvalho F, Sousa H, Ferreira AC, Sousa J, Nolasco F. Renal involvement in rheumatoid arthritis: analysis of 53 renal biopsies. Port J Nephrol. 2017. Hypert.31 19. Horak P, Smrzova A, Krejci K, Tichy T, Zadrazil J, Skacelova M. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(2):98-104. doi: 10.5507/bp.2013.042 20. Sumida K, Molnar MZ, Potukuchi PK, Hassan F, Thomas F, Yamagata K, Kalantar-Zadeh K, Kovesdy CP. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93(5):1207-16. doi: 10.1016/j.kint.2017.11.025 21. Удачкина Е.В., Новикова Д.С., Попкова Т.В. и др. Динамика липидных параметров крови у больных ревматоидным артритом на фоне комбинированной терапии тоцилизумабом и метотрексатом в сравнении с монотерапией метотрексатом при 24-недельном наблюдении. Рациональная фармакотерапия в кардиологии. 2015;11(5):510-6 [Udachkina EV, Novikova DS, Popkova TV, et al. Dynamics of blood lipid parameters in patients with rheumatoid arthritis on the background of combined therapy with tocilizumab and methotrexate in comparison with methotrexate monotherapy with 24-week follow-up. Rational Pharmacotherapy in Cardiology. 2015;11(5):510-6 (In Russ.)]. 22. Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Cur Pharm Des. 2012;18:1512-8.